TriSalus Life Sciences announced the start of patient enrollment in the PREDICTT trial, a prospective, single‑arm study conducted at the University of Texas MD Anderson Cancer Center. The trial will enroll approximately 20 adults with primary or metastatic liver tumors and will evaluate the safety and efficacy of the company’s Pressure‑Enabled Drug Delivery (PEDD) platform using Y90 radioembolization guided by its TriNav Infusion System.
The study builds on earlier investigations that demonstrated improved drug distribution and fewer complications with PEDD‑guided therapy. Positive results could support future regulatory submissions and broaden the market for TriNav, positioning TriSalus to capture a larger share of the high‑volume liver tumor indication.
TriSalus’s announcement follows a strong financial performance: Q4 2025 revenue rose 60% to $13.2 million, and FY 2025 revenue grew 53% to $45 million, while the company posted a net operating loss of $3.3 million in Q4—an improvement over the prior year’s $7.6 million loss. The company’s market capitalization was approximately $273 million as of early May 2026.
"This study represents an important step toward optimizing locoregional therapies through advanced delivery technologies," said Dr. Richard Marshall, Chief Medical Officer. The comment underscores TriSalus’s strategy to leverage its PEDD platform across multiple indications.
The PREDICTT trial is part of a broader pipeline that includes the PERIO™‑02 study of nelitolimod with PEDD for liver tumors and the PERIO™‑01 study for metastatic uveal melanoma, as well as recent product launches such as the TriNav XP and TriNav LV Infusion Systems.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.